Allosteric Enhancers: Leads for the Therapy of Cardiovascular Disease

变构增强剂：心血管疾病治疗的先导

• 批准号: DP0558184
• 负责人: Prof Peter Scammells
• 金额: $ 18.73万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-02-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0558184
• 关键词: Allosteric; Enhancers; Leads; Therapy; Cardiovascular

Cardiovascular disease (CVD - heart, stroke and blood vessel disease) kills more people each year than cancer, AIDS and traffic accidents combined. Coronary heart disease (CHD), followed by stroke, is the largest single cause of death in Australia. Allosteric enhancers are particularly attractive drug targets for the prevention of CVD due to their ability to limit injury associated with ischaemic tissue trauma selectively in tissues where adenosine is elevated. Whilst the development of drugs that protect against heart attack and stroke is a difficult and long term objective, any advances toward this goal would clearly be of great benefit to the community.

每年死于心血管疾病（心脏病、中风和血管疾病）的人比死于癌症、艾滋病和交通事故的人加起来还要多。冠状动脉心脏疾病（CHD）是澳大利亚最大的单一死因，其次是中风。变构增强剂是预防心血管疾病的特别有吸引力的药物靶点，因为它们能够在腺苷升高的组织中选择性地限制与缺血性组织创伤相关的损伤。虽然开发预防心脏病发作和中风的药物是一个困难和长期的目标，但这一目标的任何进展显然都将对社会大有裨益。